Evaluation of Dupilumab in Children With Uncontrolled Asthma
Public ClinicalTrials.gov record NCT02948959. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Children 6 to <12 Years of Age With Uncontrolled Persistent Asthma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Primary Objective: To evaluate the efficacy of dupilumab in children 6 to less than (\<) 12 years of age with uncontrolled persistent asthma. Secondary Objective: To evaluate in children 6 to \<12 years of age with uncontrolled persistent asthma: * The safety and tolerability of dupilumab. * The evaluate the effect of dupilumab in improving participant reported outcomes including health related quality of life. * The dupilumab systemic exposure and incidence of anti-drug antibodies. * The evaluate the association between dupilumab treatment and pediatric immune responses to vaccines: any vaccination for tetanus, diphtheria, pertussis and/or seasonal trivalent/quadrivalent influenza vaccine.
Study identification
- NCT ID
- NCT02948959
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 408 participants
Conditions and interventions
Conditions
Interventions
- Dupilumab Drug
- Placebo Drug
- Asthma Controller Therapies Drug
- Asthma Reliever Therapies Drug
Drug
Eligibility (public fields only)
- Age range
- 6 Years to 11 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 20, 2017
- Primary completion
- Aug 25, 2020
- Completion
- Aug 25, 2020
- Last update posted
- Mar 27, 2022
2017 – 2020
United States locations
- U.S. sites
- 18
- U.S. states
- 13
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Investigational Site Number 840031 | Birmingham | Alabama | 35209 | — |
| Investigational Site Number 840002 | Gilbert | Arizona | 85234 | — |
| Investigational Site Number 840012 | Tucson | Arizona | 85724-5030 | — |
| Investigational Site Number 840001 | Rolling Hills Estates | California | 90274 | — |
| Investigational Site Number 840036 | Owensboro | Kentucky | 42301 | — |
| Investigational Site Number 840016 | Ann Arbor | Michigan | 48106 | — |
| Investigational Site Number 840006 | St Louis | Missouri | 63110-1077 | — |
| Investigational Site Number 840022 | Lincoln | Nebraska | 68505 | — |
| Investigational Site Number 840023 | Great Neck | New York | 11021 | — |
| Investigational Site Number 840035 | New York | New York | 00000 | — |
| Investigational Site Number 840013 | New York | New York | 10032 | — |
| Investigational Site Number 840007 | Rochester | New York | 14607 | — |
| Investigational Site Number 840004 | Charlotte | North Carolina | 28277 | — |
| Investigational Site Number 840021 | Durham | North Carolina | 27710 | — |
| Investigational Site Number 840008 | Cincinnati | Ohio | 45229 | — |
| Investigational Site Number 840024 | Edmond | Oklahoma | 73034 | — |
| Investigational Site Number 840003 | San Antonio | Texas | 78229 | — |
| Investigational Site Number 840018 | La Crosse | Wisconsin | 54601 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 81 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02948959, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 27, 2022 · Synced Sep 1, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02948959 live on ClinicalTrials.gov.